English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/25086
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 27 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors

AutorMairal, Teresa; Nieto, Joan; Pinto, Marta; Almeida, Maria Rosário; Gales, Luis; Ballesteros, Alfredo; Barluenga, José; Pérez, Juan J.; Vázquez, Jesús T.; Centeno, Nuria B.; Saraiva, Maria João; Damas, Ana Margarida; Planas, Antoni; Arsequell, Gemma; Valencia Parera, Gregorio
Fecha de publicación6-ene-2009
EditorPublic Library of Science
CitaciónPLoS ONE 4(1): e4124 (2009)
ResumenThe thyroid hormone and retinol transporter protein known as transthyretin (TTR) is in the origin of one of the 20 or so known amyloid diseases. TTR self assembles as a homotetramer leaving a central hydrophobic channel with two symmetrical binding sites. The aggregation pathway of TTR into amiloid fibrils is not yet well characterized but in vitro binding of thyroid hormones and other small organic molecules to TTR binding channel results in tetramer stabilization which prevents amyloid formation in an extent which is proportional to the binding constant. Up to now, TTR aggregation inhibitors have been designed looking at various structural features of this binding channel others than its ability to host iodine atoms. In the present work, greatly improved inhibitors have been designed and tested by taking into account that thyroid hormones are unique in human biochemistry owing to the presence of multiple iodine atoms in their molecules which are probed to interact with specific halogen binding domains sitting at the TTR binding channel. The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Biochemical and biophysical evidence confirms that iodine atoms can be an important design feature in the search for candidate drugs for TTR related amyloidosis.
Descripción13 pages, 12 figures, 1 table.-- PMID: 19125186 [PubMed].-- PMCID: PMC2607018.
Versión del editorhttp://dx.doi.org/10.1371/journal.pone.0004124
URIhttp://hdl.handle.net/10261/25086
DOI10.1371/journal.pone.0004124
ISSN1932-6203 (Online)
Aparece en las colecciones: (IQAC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Mairal_Teresa_et_al.pdf985,22 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.